IXICO targets 15% revenue growth as order book swells and strategy takes shape

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), a specialist in neuroscience imaging and biomarker analytics for clinical drug trials, said it expects to deliver at least 15% revenue growth for the full year as it advances plans to open new income streams from its AI-driven platform. Chief executive Bram Goorden said a £10 million capital raise completed in April would allow the company to accelerate a "TechBio" strategy focused on integrating its IXI platform with third-party clinical trial systems and healthcare providers, stressing the funds were not needed to sustain current operations.